Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound
- PMID: 85106
- DOI: 10.1016/s0140-6736(79)90944-9
Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound
Abstract
Ingestion of 1.2 g Bay g 6575 daily for 1 week by six healthy volunteers had no effect on blood-coagulation, fibrinolysis, or platelet aggregation in vitro, but it seemed to inhibit platelet aggregation in vivo (shown by a smaller reduction in the platelet aggregate ratio after venous occlusion). Plasma drawn from five volunteers after ingestion of a single dose of 1.2 g of the drug stimulated prostacyclin release from slices of rat aorta which had been washed until they stopped releasing anti-aggregating substances, whereas plasma from the same individuals before ingestion of the substance did not. Administration of either Bay g 6575 or dipyridamole alone had no effect on platelet aggregation in vitro, but combined administration resulted in a striking and prolonged inhibition of A.D.P.-induced platelet aggregation. It is proposed that the previously described antithrombotic properties of Bay g 6575 in animals are due to stimulation of prostacyclin release from the vessel wall, and that this effect is also demonstrable in man.
Similar articles
-
Inhibition of arterial thrombosis and platelet function by nafazatrom.Thromb Res. 1982 Oct 15;28(2):157-70. doi: 10.1016/0049-3848(82)90258-4. Thromb Res. 1982. PMID: 6758186
-
Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.Lancet. 1978 Jun 17;1(8077):1286-9. doi: 10.1016/s0140-6736(78)91269-2. Lancet. 1978. PMID: 78050
-
Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.J Med. 1982;13(1-2):35-47. J Med. 1982. PMID: 6288824
-
The role of prostacyclin in vascular tissue.Fed Proc. 1979 Jan;38(1):66-71. Fed Proc. 1979. PMID: 215463 Review.
-
Platelets, thrombosis and drugs.Drugs. 1975;9(1):19-76. doi: 10.2165/00003495-197509010-00003. Drugs. 1975. PMID: 1092540 Review.
Cited by
-
Prostaglandin I2 (prostacyclin).Can Med Assoc J. 1980 Jan 26;122(2):175-9. Can Med Assoc J. 1980. PMID: 6988063 Free PMC article. Review.
-
Nafazatrom: in-vitro assessment of radiation and drug activity against animal and human cell lines.Invest New Drugs. 1984;2(1):3-6. doi: 10.1007/BF00173780. Invest New Drugs. 1984. PMID: 6469496
-
The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):267-74. doi: 10.1007/BF00634248. Naunyn Schmiedebergs Arch Pharmacol. 1985. PMID: 3841382
-
Introduction: thromboxane in biological systems and the possible impact of its inhibition.Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):7S-11S. doi: 10.1111/j.1365-2125.1983.tb02100.x. Br J Clin Pharmacol. 1983. PMID: 6337606 Free PMC article. Review. No abstract available.
-
Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.J Clin Invest. 1985 Jul;76(1):233-40. doi: 10.1172/JCI111952. J Clin Invest. 1985. PMID: 2991338 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources